Targeting Clostridioides difficile: New uses for old drugs

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Clostridioides difficile infections cause severe diarrhea and colitis, with limited treatment options and high recurrence rates.
• Developing new anti-C. difficile therapies is crucial due to treatment challenges.
• Drug repurposing is an efficient strategy for identifying novel therapeutic agents.

Purpose of the Study:

• To identify FDA-approved drugs suitable for repurposing as anti-Clostridioides difficile agents.
• To evaluate the potential of existing medications in treating C. difficile infections.
• To accelerate the development of next-generation treatments for C. difficile.

Main Methods:

• Systematic review and analysis of FDA-approved drugs for potential anti-C. difficile activity.
• Examination of existing clinical trial data for identified drug candidates.
• Focus on drugs with existing safety profiles and potential for new indications.

Main Results:

• Sixteen FDA-approved drugs were identified as candidates for C. difficile treatment.
• Five of these drugs have undergone clinical trials for various indications.
• Ursodeoxycholic acid is the only identified drug that has reached Phase IV clinical trials for C. difficile.

Conclusions:

• Drug repurposing presents a viable pathway for developing new treatments against Clostridioides difficile.
• Ursodeoxycholic acid shows promise and warrants further investigation for C. difficile therapy.
• This approach can expedite the discovery of effective anti-C. difficile agents and improve patient outcomes.